D3S-003 Clinical Trials (2026): 1 Studies for KRAS P.G12D
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 D3S-003 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including KRAS P.G12D) and 42 total planned enrollment. 1 D3S-003 clinical trial is actively recruiting at 1 U.S. site across 1 state. Most recent activity: NCT07456046 (Jan 2028).
Where to Participate: All D3S-003 Trial Sites in the U.S. (1 site across 1 state)
Every actively recruiting D3S-003trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| TX | D3 Bio Investigative Site 1402 | San Antonio78229 | NCT07456046 | Map |
D3S-003 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting D3S-003 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07456046 | A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation. | P1 | KRAS P.G12D | 42 | May 2026 |
All D3S-003 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07456046 | A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation. | P1 | recruiting | 42 | D3 Bio (Wuxi) Co., Ltd | May 2026 |
D3S-003 clinical trials: frequently asked questions
- How many D3S-003 clinical trials are there?
- 1 D3S-003 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are D3S-003 clinical trials recruiting in 2026?
- Yes — 1 D3S-003 trial is actively recruiting in 2026, with 1 U.S. site across 1 state. See the recruiting trials and the per-state site list further down this page.
- What conditions is D3S-003 being studied for?
- D3S-003 is being studied for KRAS P.G12D. The trials are grouped by indication on this page.
- What phase is D3S-003 in?
- D3S-003 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors D3S-003 clinical trials?
- The lead sponsor across the most D3S-003 trials is D3 Bio (Wuxi) Co., Ltd. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming D3S-003as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: